Filter by Event: ESCMID Global 2025
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023)
Activity of omadacycline against multidrug-resistant and molecularly characterized Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1314
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria
Zosurabalpin (5 μg) disk diffusion quality control ranges using Clinical and Laboratory Standards Institute M23 Tier 1 and Tier 2 criteria. Lead author: Michael D. Huband, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #2545
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023
Gepotidacin activity against and analysis of susceptibility to oral standard-of-care antibiotics for urinary tract infections caused by Escherichia coli and Klebsiella pneumoniae collected in Europe in 2023. Lead author: S. J. Ryan Arends, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023)
Activity of gepotidacin against molecularly characterized β-lactamase-producing E. coli and K. pneumoniae isolates from patients with urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1217
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1351
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023)
Gepotidacin activity against E. coli and K. pneumoniae, including molecularly characterized fluoroquinolone not susceptible subsets causing urinary tract infections in Europe and adjacent regions (2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1216
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres
Increase in blaNDM-1 among carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex clinical isolates collected in 2023 from U.S. and European medical centres. Lead author: John H. Kimbrough, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1273
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023). Lead author: Rodrigo E. Mendes, presented at ESCMID Global 2025, April 14, Vienna, Austria
Poster #P1349
The microbiological and clinical complexity of infections in patients with treatment-refractory Mycobacterium avium complex lung disease
The microbiological and clinical complexity of infections in patients with treatment-refractory Mycobacterium avium complex lung disease. Lead author: Timothy B. Doyle, presented at ESCMID Global 2025, April 13, Vienna, Austria
Poster #P0619
Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates
Antimicrobial activity of zosurabalpin against a diverse collection of aerobic and anaerobic bacterial and yeast isolates. Lead author: JM Maher, presented at ESCMID Global 2025, April 13, Vienna, Austria
Poster #P2350
Echinocandin susceptibility patterns and genetic changes in nonsusceptible Candida glabrata with non-hotspot FKS alterations
Echinocandin susceptibility patterns and genetic changes in nonsusceptible Candida glabrata with non-hotspot FKS alterations. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2889
Activity of manogepix against a worldwide collection of yeast isolates from 2023
Activity of manogepix against a worldwide collection of yeast isolates from 2023. Lead author: Marisa L. Winkler, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2891
Phylogenomics reveals patterns of azole activity against Aspergillus section Nigri clinical isolates.
Phylogenomics reveals patterns of azole activity against Aspergillus section Nigri clinical isolates. Lead author: John H. Kimbrough, presented at ESCMID Global 2025, April 12, Vienna, Austria
Poster #P2900
